EGFR and esophageal squamous cell carcinoma: Above all, EGFR CNG or amplification may be a promising predictive biomarker for EGFR-targeted therapy in ESCC patients, but patients with mutations in EGFR downstream effectors such as PIK3CA or BRAF may exhibit de novo resistance to afatinib.